Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 1, 2006, Pages 45-54

  Holven, K B ^a,b   Aukrust, P ^a,b   Retterstol, K ^a   Hagve, T A ^a   Morkrid L ^a   Ose, L ^a   Nenseter, M S ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Homocysteine; Inflammatory markers; Peripheral blood mononuclear cells

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 32344432647     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00335510500429821     Document Type: Article

References (32)

1. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
2. Gerald C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15.
3. Holven KB, Aukrust P, Holm T, Christensen B, Kjekshus J, Andreassen AK, et al. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 2002;22:699-703.
4. Holven KB, Halvorsen B, Schultz HB, Aukrust P, Ose L, Nenseter MS. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinemic subjects; effect of folic acid treatment. Eur J Clin Invest 2003;33:555-60.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the MRFIT Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
8. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular risk in the elderly: results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
9. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
10. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
11. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
12. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997;78:273-7.
13. Ridker P, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
14. Schumacher A, Seljeflot I, Sommervoll L, Christensen B, Otterstad JE, Arnesen H. Increased levels of markers of vascular inflammation in patients with coronary heart disease. Scand J Clin Lab Invest 2002;62:59-68.
15. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordøy I, Aas H, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
16. Holven KB, Scholz HB, Halvorsen B, Aukrust P, Ose L, Nenseter MS. Enhanced expression of lectin-like oxidized LDL receptor-1 in peripheral blood mononuclear cells of hyperhomocysteinemic subjects; effect of folic acid treatment. J Nutr 2003;133:3588-91.
17. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
18. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reductions in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002;165:361-6.
19. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
20. Lundman P, Eriksson MJ, Silveira A, Hansson LO, Pernow J, Ericsson CG, Hamsten A, Tornvall P. Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1). Am J Cardiol 2003;91:1128-31.
21. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-81.
22. Mojiminiyi OA, Abdella N, Moussa MA, Akanji AO, Al Mohammedi H, Zaki M. Association of C-reactive protein with coronary heart disease risk in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;58:37-44.
23. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997;17:1947-53.
24. Becker A, Van Hinsbergh VW, Kostense PJ, Jager A, Dekker JM, Nijpels G, et al. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule-1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects: The Hoorn Study. Eur J Clin Invest 2000;30:763-70.
25. Bayes B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003;18:106-12.
26. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9.
27. Auer JW, Berent R, Eber B. Lack of association of increased C-reactive protein and total plasma homocysteine. Circulation 2001;104:E164.
28. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
29. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103:2788-91.
30. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.
31. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8.
32. van Aken BE, Jansen J, van Deventer SJ, Reitsma PH. Elevated levels of homocysteine increase IL-6 production in monocytic mono mac 6 cells. Blood Coagul Fibrinolysis 2000;2:159-64.